First-generation GHRP largely superseded by cleaner alternatives, appetite signal is interesting but not enough
Look, GHRP-6 has a story, but its best chapters were written in the 1990s. It’s a first-generation hexapeptide, one of the original compounds that validated the ghrelin receptor as a viable target for GH secretagogues, and for that it deserves some historical respect. But history isn’t a research rationale.
The mechanism is exactly what you’d expect from something this old: GHSR1a agonism, pulsatile GH release, appetite stimulation through the ghrelin pathway. Solid, well-understood, extensively mapped. The problem is it also drags cortisol and prolactin up in a way that the later-generation GHRPs largely avoid. Ipamorelin came along specifically to solve that problem. Researchers moved on. The cortisol/prolactin elevation isn’t just a safety nuisance in animal models, it complicates any experiment where you’re trying to isolate GH-axis effects. That’s a real methodological liability.
Differentiation is where GHRP-6 genuinely suffers. We think of it mostly as a less clean GHRP-2 or a more side-effect-prone ipamorelin. There’s almost no scenario where it’s the first choice over those two unless you’re specifically studying appetite modulation via ghrelin, which is the one corner where GHRP-6 has a distinctive profile. The appetite stimulation is pronounced and reproducible, and if thats the actual research question, it becomes a relevant tool. Cachexia or sarcopenia models where caloric intake is the outcome variable, for instance. But that is a narrow carve-out, not a broad program.
Evidence quality is moderate. Decades of multi-lab preclinical data exist, and there’s some human work from the 1990s and early 2000s on GH secretion dynamics. But clinical development stalled out, and theres essentially no modern RCT infrastructure behind it. The human translational story is capped by that abandoned trajectory. We’re not looking at a compound with fresh phase 2 data or a revived indication pipeline. What we’re looking at is a reference compound for ghrelin receptor agonism that has been functionally replaced in most experimental designs.
The bench value survives in one specific context: if you’re running a comparative GHRP study and need a first-generation reference point, or if appetite/orexigenic signaling is central to your model, GHRP-6 earns its spot. Outside that, we’d suggest the investigator ask whether ipamorelin or GHRP-2 actually answers their question better before reaching for this one. Most of the time, the answer is yes. That’s the honest position here: not a bad compound, just not the right compound for most research programs that have access to better options.